Líffræðifélag Íslands
Líffræðiráðstefnan 2015
Erindi/veggspjald / Talk/poster E37
Jon G Jonasson (1,2,3), Olafur A Stefansson (4), Oskar T Johannsson (2,5,6), Helgi Sigurdsson (2,5), Bjarni A Agnarsson (2,3), Gudridur H Olafsdottir (1), Kristin K Alexiusdottir (1,5), Hrefna Stefansdottir (1), Rodrigo Munoz Mitev (3), Katrin Olafsdottir (3), Kristrun Olafsdottir (3), Adalgeir Arason (7), Vigdis Stefansdottir (6), Elinborg J Olafsdottir (1), Rosa B Barkardottir (2,7,8), Jorunn E Eyfjord (2,4), Steven A Narod (9), Laufey Tryggvadottir (1,2).
1. Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland, 2. Faculty of Medicine, Laeknagardur, University of Iceland, Reykjavik, Iceland, 3. Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland, 4. Cancer Research Laboratory, Biomedical Centre, School of Health Sciences, University of Iceland, 5. Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland, 6. Department of Genetics and Molecular Medicine, University Hospital, Reykjavik, Iceland, 7. Laboratory of Cell Biology, Department of Pathology, University Hospital, Reykjavik, Iceland, 8. Biomedical Centre, School of Health Sciences, University of Iceland, Reykjavik, Iceland, 9. Womens’ College Research Institute, University of Toronto, Toronto, Ontario, Canada
Kynnir / Presenter: Laufey Tryggvadóttir
Tengiliður / Corresponding author: Laufey Tryggvadóttir (laufeyt@krabb.is)
"Background Mutations in the BRCA2 gene are associated with a highly increased risk of breast cancer. However, little is known of specific effects of prognostic factors and treatment on survival among those patients. Material & methods We compared the risk of breast cancer-specific death according to status of prognostic factors and treatment between 285 female patients carrying the Icelandic BRCA2 999del5 founder mutation and 570 non-carriers diagnosed 1935-2012. Clinical information was abstracted from patient charts and pathology records, supplemented by grading and evaluation of ER status using archival tissue specimens. Multivariate Hazard ratios (HRs) were estimated using Cox regression. Results In an adjusted analysis, BRCA2 mutation was a significant adverse prognostic factor (HR = 1.66; 95% CI 1.22-2.24, p = 0.001). Contrary to expectation, a positive ER status was an adverse prognostic factor in the BRCA2 positive subgroup, both among women diagnosed in 1980-2012 (HR = 1.82; 95% CI 0.97-3.40, p = 0.06) and before the introduction of hormone therapy (1935-1979) (HR = 1.97; 95% CI 0.98-3.94, p = 0.06). The advantage from treatment with mastectomy and chemotherapy was greater among mutation carriers than non-carriers. Conclusion The results indicate that a positive ER status predicts adverse outcome among mutation carriers and that BRCA2 carrier status should be known when treatment decisions are made."